Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Health-related quality of life outcomes from KEYNOTE-412: chemoradiotherapy with or without pembrolizumab in participants with head and neck squamous cell carcinoma.

Frontiers in oncology·2025
Same author

Characterizing and Targeting of BCL-2 Family Members in Nasopharyngeal Carcinoma.

Head & neck·2024
Same author

Prognostic stratification of HPV-associated oropharyngeal cancer based on CD103<sup>+</sup> immune cell abundance in patients treated on TROG 12.01 and De-ESCALaTE randomized trials.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Identification of an excellent prognosis subset of human papillomavirus-associated oropharyngeal cancer patients by quantification of intratumoral CD103+ immune cell abundance.

Annals of oncology : official journal of the European Society for Medical Oncology·2019
Same author

Diabetes associated with immune checkpoint inhibition: presentation and management challenges.

Diabetic medicine : a journal of the British Diabetic Association·2018
Same author

How do the two visual streams interact with each other?

Experimental brain research·2017

Related Experiment Video

Updated: Jul 11, 2026

Retroductal Submandibular Gland Instillation and Localized Fractionated Irradiation in a Rat Model of Salivary Hypofunction
07:44

Retroductal Submandibular Gland Instillation and Localized Fractionated Irradiation in a Rat Model of Salivary Hypofunction

Published on: April 24, 2016

Parotid-sparing radiotherapy: does it really reduce xerostomia?

M K Ng1, S V Porceddu, A D Milner

  • 1Department of Radiation Oncology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia. ngmichael@petermac.org

Clinical Oncology (Royal College of Radiologists (Great Britain))
|December 24, 2005
PubMed
Summary

Parotid-sparing radiotherapy (PSRT) significantly reduces long-term xerostomia (dry mouth) compared to conventional radiotherapy for head and neck cancers. Patients receiving PSRT reported better quality of life due to less severe dry mouth symptoms.

More Related Videos

Murine Salivary Functional Assessment via Pilocarpine Stimulation Following Fractionated Radiation
09:10

Murine Salivary Functional Assessment via Pilocarpine Stimulation Following Fractionated Radiation

Published on: May 4, 2018

Radiation Treatment of Organotypic Cultures from Submandibular and Parotid Salivary Glands Models Key In Vivo Characteristics
07:38

Radiation Treatment of Organotypic Cultures from Submandibular and Parotid Salivary Glands Models Key In Vivo Characteristics

Published on: May 17, 2019

Related Experiment Videos

Last Updated: Jul 11, 2026

Retroductal Submandibular Gland Instillation and Localized Fractionated Irradiation in a Rat Model of Salivary Hypofunction
07:44

Retroductal Submandibular Gland Instillation and Localized Fractionated Irradiation in a Rat Model of Salivary Hypofunction

Published on: April 24, 2016

Murine Salivary Functional Assessment via Pilocarpine Stimulation Following Fractionated Radiation
09:10

Murine Salivary Functional Assessment via Pilocarpine Stimulation Following Fractionated Radiation

Published on: May 4, 2018

Radiation Treatment of Organotypic Cultures from Submandibular and Parotid Salivary Glands Models Key In Vivo Characteristics
07:38

Radiation Treatment of Organotypic Cultures from Submandibular and Parotid Salivary Glands Models Key In Vivo Characteristics

Published on: May 17, 2019

Area of Science:

  • Radiation Oncology
  • Head and Neck Cancer Treatment
  • Quality of Life Research

Background:

  • Parotid-sparing radiotherapy (PSRT) was implemented in 2000 for head and neck cancer patients requiring bilateral upper-neck irradiation.
  • Conventional radiotherapy techniques often lead to significant xerostomia (dry mouth).

Purpose of the Study:

  • To compare the subjective experience of xerostomia in patients treated with PSRT versus conventional radiotherapy.
  • To evaluate the long-term quality of life impact of different radiotherapy techniques on xerostomia.

Main Methods:

  • A retrospective study comparing 38 patients treated with PSRT (mean parotid dose ≤33 Gy) and 44 patients treated with conventional radiotherapy (minimum parotid dose ≥40 Gy).
  • Xerostomia was assessed using a validated 6-question questionnaire (0-10 scale, lower scores indicate less difficulty).
  • Patients were interviewed at least 6 months post-treatment and required to be recurrence-free.

Main Results:

  • Patients treated with PSRT reported a significantly lower mean xerostomia score (4.20) compared to those receiving conventional radiotherapy (5.86) (P < 0.001).
  • Individual question scores related to xerostomia were also significantly better in the PSRT group.
  • The study included patients with oropharyngeal and nasopharyngeal cancers.

Conclusions:

  • PSRT demonstrates a significant benefit in reducing long-term xerostomia.
  • These findings suggest improved quality of life for head and neck cancer patients treated with parotid-sparing radiotherapy compared to conventional methods.